We are dedicated to developing the next generation of targeted drugs for treatment of human cancer.
Curis is an oncology-focused drug development company committed to developing novel drug candidates paired for specific cancer indications. Curis is building upon its previous experiences, including targeting the Hedgehog pathway by the approved drug, Erivedge®, to further the advancement of its proprietary pipeline of targeted cancer programs. Learn more »